Post Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Post Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $8.16B | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $7.92B | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $6.99B | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | $5.85B | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $4.98B | Nov 17, 2023 |
| FY2020 | Sep 30, 2020 | $1.41B | Nov 20, 2020 |
| FY2020 | Jun 30, 2020 | $1.34B | Nov 20, 2020 |
| FY2020 | Mar 31, 2020 | $1.49B | Nov 20, 2020 |
| FY2020 | Dec 31, 2019 | $1.46B | Nov 20, 2020 |
| FY2020 | Sep 30, 2019 | $1.44B | Nov 20, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $2.34B | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $2.30B | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $1.88B | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | $1.47B | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $1.43B | Nov 17, 2023 |
| FY2020 | Sep 30, 2020 | $440.30M | Nov 20, 2020 |
| FY2020 | Jun 30, 2020 | $436.80M | Nov 20, 2020 |
| FY2020 | Mar 31, 2020 | $438.80M | Nov 20, 2020 |
| FY2020 | Dec 31, 2019 | $471.50M | Nov 20, 2020 |
| FY2020 | Sep 30, 2019 | $452.20M | Nov 20, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $335.70M | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $366.70M | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $301.30M | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | $756.60M | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $166.70M | Nov 17, 2023 |
| FY2020 | Sep 30, 2020 | $57.00M | Nov 20, 2020 |
| FY2020 | Jun 30, 2020 | $36.00M | Nov 20, 2020 |
| FY2020 | Mar 31, 2020 | ($191.40M) | Nov 20, 2020 |
| FY2020 | Dec 31, 2019 | $99.20M | Nov 20, 2020 |
| FY2020 | Sep 30, 2019 | ($61.10M) | Nov 20, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $799.30M | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $793.50M | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $598.90M | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | $415.60M | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $487.70M | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | $536.50M | Nov 17, 2022 |
| FY2021 | Sep 30, 2019 | $781.00M | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $573.50M | Nov 20, 2020 |
| FY2019 | Sep 30, 2017 | $516.70M | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $545.70M | Nov 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $31.90M | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $29.00M | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $22.90M | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | $18.90M | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $21.90M | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | $19.10M | Nov 17, 2022 |
| FY2021 | Sep 30, 2019 | $25.00M | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $25.10M | Nov 20, 2020 |
| FY2019 | Sep 30, 2017 | $18.60M | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $16.30M | Nov 16, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $1.31B | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $1.33B | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $1.08B | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | $904.70M | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $807.00M | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | $782.50M | Nov 17, 2022 |
| FY2021 | Sep 30, 2019 | $911.60M | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $976.40M | Nov 20, 2020 |
| FY2019 | Sep 30, 2017 | $867.70M | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $839.70M | Nov 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $998.30M | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $931.70M | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $750.30M | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | $382.60M | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $588.20M | Nov 17, 2023 |
| FY2022 | Sep 30, 2020 | $625.60M | Nov 17, 2022 |
| FY2021 | Sep 30, 2019 | $688.00M | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $718.60M | Nov 20, 2020 |
| FY2019 | Sep 30, 2017 | $386.70M | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $502.40M | Nov 16, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $13.53B | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $12.85B | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $11.65B | Nov 21, 2025 |
| FY2023 | Sep 30, 2022 | $11.31B | Nov 17, 2023 |
| FY2022 | Sep 30, 2021 | $12.41B | Nov 17, 2022 |
| FY2021 | Sep 30, 2020 | $12.15B | Nov 19, 2021 |
| FY2021 | Sep 30, 2019 | $11.95B | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $13.06B | Nov 20, 2020 |
| FY2019 | Sep 30, 2017 | $11.88B | Nov 22, 2019 |
| FY2018 | Sep 30, 2016 | $9.36B | Nov 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $9.76B | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $8.75B | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $7.80B | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $7.74B | Nov 17, 2023 |
| FY2022 | Sep 30, 2021 | $9.36B | Nov 17, 2022 |
| FY2021 | Sep 30, 2020 | $9.32B | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | $9.01B | Nov 20, 2020 |
| FY2019 | Sep 30, 2018 | $10.00B | Nov 22, 2019 |
| FY2018 | Sep 30, 2017 | $9.09B | Nov 16, 2018 |
| FY2017 | Sep 30, 2016 | $6.35B | Nov 17, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $3.75B | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $4.09B | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $3.84B | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $3.25B | Nov 17, 2023 |
| FY2022 | Sep 30, 2021 | $2.74B | Nov 17, 2022 |
| FY2021 | Sep 30, 2020 | $2.85B | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | $2.93B | Nov 20, 2020 |
| FY2019 | Sep 30, 2018 | $3.05B | Nov 22, 2019 |
| FY2018 | Sep 30, 2017 | $2.78B | Nov 16, 2018 |
| FY2017 | Sep 30, 2016 | $3.01B | Nov 17, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $4.84B | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $4.70B | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $4.57B | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $4.35B | Nov 17, 2023 |
| FY2022 | Sep 30, 2021 | $4.50B | Nov 17, 2022 |
| FY2021 | Sep 30, 2020 | $4.44B | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | $4.40B | Nov 20, 2020 |
| FY2019 | Sep 30, 2018 | $4.50B | Nov 22, 2019 |
| FY2018 | Sep 30, 2017 | $4.03B | Nov 16, 2018 |
| FY2017 | Sep 30, 2016 | $3.08B | Nov 17, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $2.12B | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $1.78B | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $1.42B | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $1.11B | Nov 17, 2023 |
| FY2022 | Sep 30, 2021 | $347.30M | Nov 17, 2022 |
| FY2021 | Sep 30, 2020 | $208.60M | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | $207.80M | Nov 20, 2020 |
| FY2019 | Sep 30, 2018 | $88.00M | Nov 22, 2019 |
| FY2018 | Sep 30, 2017 | ($376.00M) | Nov 16, 2018 |
| FY2017 | Sep 30, 2016 | ($424.30M) | Nov 17, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | $176.70M | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | $787.40M | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | $93.30M | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $586.50M | Nov 17, 2023 |
| FY2022 | Sep 30, 2021 | $664.50M | Nov 17, 2022 |
| FY2021 | Sep 30, 2020 | $1.19B | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | $1.05B | Nov 20, 2020 |
| FY2019 | Sep 30, 2018 | $989.70M | Nov 22, 2019 |
| FY2018 | Sep 30, 2017 | $1.53B | Nov 16, 2018 |
| FY2018 | Sep 30, 2016 | $1.14B | Nov 16, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Sep 30, 2016 | $4.55B | Nov 18, 2016 |
| FY2016 | Sep 30, 2015 | $4.45B | Nov 18, 2016 |
| FY2015 | Sep 30, 2014 | $3.83B | Nov 25, 2015 |
| FY2014 | Sep 30, 2013 | $1.41B | Nov 28, 2014 |
| FY2013 | Sep 30, 2012 | $930.30M | Nov 27, 2013 |
| FY2012 | Sep 30, 2011 | $0 | Dec 13, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | 5 | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | 6 | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | 5 | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | 12 | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | 2 | Nov 17, 2023 |
| FY2020 | Sep 30, 2020 | 0 | Nov 20, 2020 |
| FY2020 | Jun 30, 2020 | 0 | Nov 20, 2020 |
| FY2020 | Mar 31, 2020 | (2) | Nov 20, 2020 |
| FY2020 | Dec 31, 2019 | 1 | Nov 20, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Nov 20, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2025 | 5 | Nov 21, 2025 |
| FY2024 | Sep 30, 2024 | 5 | Nov 21, 2025 |
| FY2024 | Sep 30, 2023 | 4 | Nov 21, 2025 |
| FY2024 | Sep 30, 2022 | 12 | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | 2 | Nov 17, 2023 |
| FY2020 | Sep 30, 2020 | 0 | Nov 20, 2020 |
| FY2020 | Jun 30, 2020 | 0 | Nov 20, 2020 |
| FY2020 | Mar 31, 2020 | (2) | Nov 20, 2020 |
| FY2020 | Dec 31, 2019 | 1 | Nov 20, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Nov 20, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Sep 30, 2012 | 32.65M | Dec 13, 2012 |